Amgen expects generic biologics
"Generic biologics will happen and I think we'll see them in Europe first," Amgen CEO Kevin Sharer told investors Feb. 25. The exec noted that generic biologics are "profoundly different" from conventional generic drugs, citing the need to conduct clinical trials and the larger required investment in manufacturing facilities as examples. Sharer expects that Amgen's Epogen (epoetin alfa) in Europe would be the company's first product to face generic competition; however, the CEO said, "from our patent lives here in the U.S. and for the newer products in Europe, it's a long way out for us"...
You may also be interested in...
The European Union approach to follow-on biologic products sets an "appropriate" standard, the Biotechnology Industry Organization said
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.